Baldwin Park Apartments Acquired by Affordable Housing Developer for $23.3 Million
'The renovations at Ramona Park reflect our ongoing commitment to preserving and enhancing affordable housing in Metro Los Angeles, where the need has never been greater. With more than 500,000 low-income households in the region struggling to find affordable rental options, it is critical that we invest in maintaining and modernizing these communities,' said Belinda Lee, vice president of development at CPP, in a statement.
This acquisition is the organization's fourth project in the Los Angeles area over the past year. Ramona Park is comprised of eight two-story, garden-style buildings with one-, two- and three-bedroom units.
Renovations include both interior and exterior cosmetic upgrades, such as windows, flooring, cabinets and countertops. It will also enhance the facility to add ADA-compliant units, and pathways will be enhanced to meet local accessibility requirements. New resident amenities will feature a picnic area, bike racks, a business center, social services and surveillance cameras.
Information for this article was sourced from Community Preservation Partners.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 days ago
- Business Upturn
ShariaPortfolio Wealth Group Surpasses $2 Billion in Assets Under Management
LAKE MARY, Fla., Aug. 08, 2025 (GLOBE NEWSWIRE) — The ShariaPortfolio Group of Companies (SP Wealth) is proud to celebrate a significant achievement in its pursuit of financial excellence: $2 billion in Assets Under Management (AUM) as of May 2, 2025. This milestone underscores the firm's commitment to delivering Sharia-compliant, ethically sound investment strategies that align with the financial goals and values of its diverse client base. A standout contributor to this success is SPUS, the group's flagship ETF, which alone has grown to over $1.2 billion in assets as of May 9, 2025, a remarkable achievement that demonstrates strong investor confidence in Sharia-compliant equity solutions. SPUS remains a cornerstone in the firm's ETF lineup and a benchmark for ethical investing. The SP Wealth Group of Companies, including SP Funds, continues to innovate within the Islamic finance space. Notably, the firm has introduced a suite of 11 innovative funds, including a unique series of (6) Target Date Funds (TDFs) that address the needs of long-term savers in vehicles like 401(k) and 529 plans. These TDFs stand out in the market for their faith-aligned design, offering a compelling alternative for retirement and education planning. 'With our 11 funds—especially the Target Date Funds—we are not only innovating but also filling a critical gap in the market,' said Naushad Virji, CEO of SP Funds. 'These are not just products; they are purpose-driven solutions that support the long-term goals of investors seeking Sharia-compliant options.' Within the broader funds category, SP Wealth has strategically developed five ETFs that span a wide range of asset classes. This comprehensive offering provides individual investors with a well-rounded toolkit—an arsenal of investment options—to build diversified, ethically grounded portfolios. 'Our milestone of surpassing $2 Billion in assets under management is a testament to the trust our clients have placed in us and the effectiveness of our Sharia-compliant investment strategies,' said Virji. 'This success is not only a reflection of our growth but also of our unwavering commitment to upholding the highest ethical standards in everything we do.' Since its inception in 2003, the SP Wealth Group of Companies has remained dedicated to providing financial solutions rooted in the principles of Halal Investing. The company's iconic shield logo symbolizes this mission—representing the protection of clients from excessive debt and non-compliant investments, while guiding them toward financial security and purpose-driven growth. 'Reaching $2 billion in assets under management marks a major milestone in our journey, but it's only the beginning,' Virji added. 'As we continue to grow, our focus remains on expanding access to responsible, Sharia-compliant investment solutions and delivering exceptional value to our clients worldwide.' For more information about the SP Wealth Group of Companies and its range of Sharia-compliant financial solutions, please visit About SP Wealth: The ShariaPortfolio Wealth Group of Companies is a leading financial services provider committed to offering comprehensive Sharia-compliant investment solutions and personalized financial advice to individuals, families, and institutions. With a focus on integrity, transparency, and excellence, the SP Group helps clients achieve their financial goals and build a secure future. The firm's signature shield logo reflects its dedication to protecting clients from investments with significant debt and those that do not align with their personal values. With over $2 billion in assets under management—including over $1.2 billion in SPUS—the SP Wealth Group remains a trusted partner in financial success. Important Information: Before investing, you should carefully consider the Fund's investment objectives, risks, charges, and expenses. This and other information is available in the prospectus. A prospectus can be obtained by visiting | SPUS Prospectus | SPSK Prospectus | SPRE Prospectus | SPTE Prospectus | SPWO Prospectus Investing involves risk, including the loss of Fund Services, LLC, DistributorContact: Naushad Virji, CEO, SP Funds Email: [email protected]
Business Journals
3 days ago
- Business Journals
From concept to capacity — Faster parking for South Florida's healthcare systems
For healthcare administrators and real estate developers, parking isn't just a line item, it's a critical part of patient experience and operational flow. But building new structured parking on an active medical campus? That's where things get complicated. You're balancing permit approvals, tight site logistics, and stakeholder pressure—all while trying to avoid service disruption and keep costs predictable. That's why some of Florida's leading hospital systems are turning to partners who've done this before—many times over. With more than two dozen healthcare parking structures completed across the state, FINFROCK understands the stakes. We've delivered for major systems in Miami, Orlando, Jacksonville, and beyond, solving complex challenges while keeping timelines and budgets on track. Built for the Pace (and Pressure) of Healthcare FINFROCK has designed, manufactured, and constructed more healthcare parking structures in Florida than any other firm. With over 300 precast parking structures nationwide and more than two dozen hospital-related projects completed statewide—including major facilities in Miami, Boca Raton, Orlando, and Jacksonville, our team understands the operational demands that come with building on a healthcare campus. We know what it means to stage materials in tight footprints. We know how to phase work around emergency access routes. We know how to communicate with facilities teams to keep disruptions low. And most of all, we know how to finish on time. Even when the schedule is aggressive. expand Unlike typical construction firms, FINFROCK is a vertically integrated design-builder. That means we combine architecture, engineering, precast concrete manufacturing, and general contracting under one roof. The result? A seamless process where pricing, design, and construction planning happen concurrently, eliminating guesswork and giving you cost certainty from the start. expand When you work with FINFROCK, there's no need to manage handoffs between multiple firms. You're working with one experienced partner who owns the entire process—from concept to capacity. And because our structures are manufactured in-house, we can maintain a pace that other builders simply can't match while maintaining strict quality standards and structural durability built for decades of 24/7 hospital traffic. Unlike traditional cast-in-place methods where the focus often ends at the first pour, FINFROCK's precast concrete is a true lifecycle solution, designed and built with longevity, efficiency, and long-term value in mind. As both architect and builder, we consider how a structure will perform for decades, not just how it stands on day one. Check out the Case Study: Boca Raton Regional Hospital What This Means for Your Project Modular, integrated delivery isn't a gimmick—it's a strategic tool. Here's how it works for healthcare: You get an early, reliable price—before drawings are set Design issues—ranging from utilities to ADA access—get resolved fast Construction cranes can work efficiently between active buildings Parking becomes an asset, not a liability, improving patient and staff experience Capacity on Your Terms Building for healthcare means hitting delivery dates without jeopardizing patient access, budgets, or safety. With FINFROCK's advanced modular and single-source model, capacity comes on your terms: fast, efficient, and predictable. If delivering parking for your South Florida healthcare project is on the table, talk to FINFROCK early. We simplify the infrastructure behind the care so your teams can focus on what matters most. Don't let parking delay your healthcare development. FINFROCK helps hospitals and medical centers get spaces online faster with integrated design-build solutions. Contact us to get started. FINFROCK, Florida's top design-builder, integrates architects, engineers, manufacturing, and construction professionals to lower costs, speed-up schedules, and minimize building risk for owners. With over 75+ years' experience, FINFROCK has delivered award-winning buildings including parking, hotels, and luxury multi-family developments, earning top industry rankings and multiple design excellence awards. Dan Helmick, PE, executive VP of project development, propels multi-million-dollar projects, securing key developments with his design and sales background. His strategic vision ensures success, a vital asset to FINFROCK's leadership team.
Yahoo
3 days ago
- Yahoo
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Transplant Pancreatic Islet Cells Without Immunosuppression and Overcome Both Allogeneic and Autoimmune Rejection Six-Month Patient Follow-up Results Presented at the 85th Annual American Diabetes Association (ADA) Scientific Sessions Further Demonstrate that Sana's HIP-Modified Pancreatic Islet Cells are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient Sana Is Incorporating its HIP Technology to Develop SC451, a HIP-Modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal Blood Glucose with No Insulin and No Immunosuppression Recent FDA INTERACT Meeting Increases Confidence in Moving Forward with GMP Master Cell Bank for SC451 and in Filing SC451 Investigational New Drug Application (IND) as Early as 2026 Sana Expects Study Data to Be Generalizable across Multiple Cell Types and Patient Populations SEATTLE, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the New England Journal of Medicine (NEJM) has published a journal article titled 'Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression' (DOI: 10.1056/NEJMoa2503822). The article discusses 12-week results from an investigator-sponsored trial, conducted at Uppsala University Hospital, evaluating the transplantation of UP421, a primary human pancreatic islet cell therapy engineered with Sana's hypoimmune (HIP) technology, without the use of immunosuppressive medications in a 42-year-old patient living with type 1 diabetes for over three decades. The intramuscular transplantation of HIP-modified pancreatic islet cells is safe and well-tolerated and demonstrates that these cells evade autoimmune and allogeneic immune recognition, persist, and secrete insulin in a glucose-dependent manner over the 12-week evaluation period reported in the article. 12-week PET-MRI scanning also confirmed islet cells at the transplant site. Six-month data, described below, were recently presented at the ADA meeting and presented today at the World Transplant Congress 2025 concurrently with the publication of the NEJM article. 'We are thrilled to have the results of this study, which we believe represent both a scientific and medical breakthrough, recognized in the New England Journal of Medicine,' said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. 'Type 1 diabetes is a disease in which the immune system destroys the beta cells in pancreatic islets, requiring the patient to receive lifelong insulin therapy to control glucose levels. Although it is well established that pancreatic islet cell transplantation at a target therapeutic dose can predictably allow patients with type 1 diabetes to live without insulin therapy, until now these patients must take lifelong, significant immunosuppression, which is frequently toxic and difficult to tolerate. This study shows that Sana's novel HIP-modified pancreatic islets restore insulin production without the need for immunosuppression, a transformative outcome and significant step toward a broadly accessible, functional cure for patients with type 1 diabetes. The patient is making his own insulin for the first time in over 35 years.' 'These peer-reviewed results, built upon the extensive preclinical and translational studies of Dr. Sonja Schrepfer and the team at Sana, reinforce our belief that Sana has the capability to develop a functional cure for the broad population of individuals living with type 1 diabetes,' said Steve Harr, MD, Sana's President and Chief Executive Officer. 'The data, together with recent FDA feedback regarding our HIP-edited master cell bank for GMP manufacturing and our non-clinical testing plan for SC451, increase our confidence in our goal for treating type 1 diabetes—a single treatment with no immunosuppression that leads to long-term normal blood glucose without exogeneous insulin. We expect to file an IND for SC451, a next generation HIP-modified, stem cell-derived pancreatic islet therapy, as early as 2026 and begin Phase 1 testing shortly thereafter. I want to thank the entire Sana team, the investigators at Uppsala, and the patient who volunteered for this transformative, first-in-human study.' James Shapiro, M.D., Professor of Surgery, Medicine, and Surgical Oncology at the University of Alberta and leader of the clinical team that developed the Edmonton Protocol for islet cell transplantation, added 'Exogenous insulin therapy remains a lifesaving therapy in the short term, but it falls short of replicating the precise and dynamic glucose regulation of a healthy pancreas, leaving patients susceptible to both short- and long-term medical complications. This limitation motivated my team and me to pioneer a protocol for islet cell transplantation with immunosuppression and to continue innovating in this field. The data presented in the NEJM article—demonstrating that transplanted, engineered islet cells can both evade immune-mediated destruction and respond appropriately to insulin demands—represent a significant advancement in the ongoing pursuit of a definitive cure for type 1 diabetes and support my long-held belief that the future of type 1 diabetes treatment is in stem cell-based therapies.' Key Findings from Ongoing Study No serious adverse events or adverse events possibly or probably related to UP421 were identified in the study. HIP-modified pancreatic islet cells, transplanted with no immunosuppressive medicines, including no glucocorticoids, evade immune detection and rejection. Pancreatic islet cells survive and function post-transplantation. The survival and function of the HIP-modified pancreatic beta cells was confirmed at each blood draw, as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels increase during monthly mixed meal tolerance tests (MMTT), showing increased insulin secretion in response to a meal. Of note, prior to transplant, the patient had undetectable C-peptide both when fasting and during an MMTT. MRI scans at each month show a sustained and consistent signal at the site of cell transplantation, consistent with graft survival. A PET-MRI scan with a tracer targeting pancreatic beta cells confirms that the surviving cells are, in fact, pancreatic beta cells. Sign in to access your portfolio
